1427549-75-4

Upstream product

• 71666-48-3 2-cyclohexyl-1-(4-fluorophenyl)ethanone 
• 1427549-78-7 1-(4-fluorophenyl)-2-(1-hydroxycyclohexyl)ethan-1-one 
• 108-94-1 cyclohexanone 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 1427549-89-0 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H-imidazo[1,2-b]pyrazole-6-carboxylic acid 
• 7524-52-9 (S)-tryptophan methyl ester hydrochloride 
• 1427549-87-8 methyl 3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-imidazo[1,2-b]pyrazole-6-carboxylate 
• 1427549-83-4 methyl 3-cyclohexyl-2-(4-fluorophenyl)-1H-imidazo[1,2-b]pyrazole-6-carboxylate 
• 1427549-81-2 2-bromo-2-cyclohexyl-1-(4-fluorophenyl)ethanone 

Downstream Products

• 1427549-76-5 N-{[3-cyclohexyl-2-(4-fluorophenyl)-1-methyl-1H-imidazo[1,2-b]pyrazole-6-yl]carbonyl}-L-tryptophan 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF HCV

The present invention relates to viral polymerase inhibitors of formula (I), salts, solvates, hydrates, racemates, enatiomers and isomers thereof, in particular inhibitors of viral polymerases within the Flaviviridae family such as hepatitis C virus (HCV), processes for their preparation and their use in the treatment of Flaviviridae viral infection such as Hepatitis C virus (HCV) infections